Page 10 - Cell Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results March 04, 2021 16:42 ET | Source: Cellectis Inc. Cellectis Inc. New York, New York, UNITED STATES Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers Preliminary results from our Phase 1 BALLI-01 clinical study of UCART22 in adults with r/r B-ALL presented in oral session at 2020 ASH Annual Meeting Partner A...

Study demonstrates intricate relationship between Prpf19 and Exoc7 in inherited ataxias Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph Disease (MJD), describes the most common form of dominantly inherited ataxia in many populations worldwide, including Hong Kong and mainland China. SCA3 or MJD patients often present problems with gait and balance, blurred vision, and speech difficulties. The symptoms are progressive, and patients may eventually decline into a bed-ridden state. To date, SCA3 or MJD remains an incurable disorder. Collaborating with the University of Oxford, ...

Work has potential implications for new therapies to treat cancer and neurodegenerative disorders A team of Case Western Reserve University researchers has found a way to measure key characteristics of proteins that bind to RNA in cells-a discovery that could improve our understanding of how gene function is disturbed in cancer, neurodegenerative disorders or infections. RNA-short for ribonucleic acid-carries genetic instructions within the body. RNA-binding proteins play an important role in the regulation of gene expression. Scientists already knew that the way these proteins function depen...

Researchers from Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer.

EGR1 protein acts as a master regulator of inflammation in macrophages, study suggests Scientists at The Wistar Institute discovered that Early Growth Response 1 (EGR1), a protein that turns on and off specific genes during blood cell development, inhibits expression of pro-inflammatory genes in macrophages. As part of their function to protect the body against pathogens, macrophages play a major role in initiation, maintenance, and resolution of inflammation. The discovery expands the understanding of how macrophages are set off and deactivated in the inflammatory process, which is critical ...